Comparative In Vitro Activities of Nemonoxacin (TG-873870), a Novel Nonfluorinated Quinolone, and Other Quinolones against Clinical Isolates

Abstract

The in vitro antibacterial activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, against 770 clinical isolates were investigated. Nemonoxacin (tested as its malate salt, TG-875649) showed better in vitro activity than ciprofloxacin and levofloxacin against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenzae. The in vitro activity of TG-875649 was also comparable to or better than that of moxifloxacin against these pathogens, which included ciprofloxacinresistant, methicillin-resistant Staphylococcus aureus and levofloxacin-resistant Streptococcus pneumoniae.

Investigational Antimicrobial Agents of 2013

“…It has completed phase 2 studies for community-acquired pneumonia (CAP) and for diabetic foot infections; recruitment is in progress for a phase 3 trial in CAP (http://www.clinicaltrials.gov). Nemonoxacin has a broad spectrum of activity against Gram-positive, Gram-negative, and atypical pathogens, including activity against methicillin-resistant Staphylococcus aureus (MRSA) (MIC 90 ϭ 1 g/ml) and vancomycin-resistant pathogens (17,18). However, it was less active against Gram-negative pathogens such as Escherichia coli, Proteus mirabilis, and Pseudomonas aeruginosa, with MIC 90 values of 32, 16, and 32 g/ml, respectively (18,19).…”

In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone Antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae

“…The MICs for nemonoxacin of the fluoroquinolone-resistant N. gonorrhoeae isolates were 0.25 to 1 g/ml, which were 2-to 4-fold higher than the MICs for ciprofloxacin, levofloxacin, and moxifloxacin (9).…”

“…Nemonoxacin has excellent activity in vitro and in vivo against respiratory pathogens, including methicillin-and vancomycinresistant Staphylococcus aureus, levofloxacin-resistant and penicillin-resistant Streptococcus pneumoniae, and Haemophilus influenzae (6)(7)(8)(9). Oral nemonoxacin, 750 mg and 500 mg given once daily for 7 days, showed high biological success rates for common bacterial pathogens and high clinical success rates for atypical pathogens of community-acquired pneumonia.…”

“…It has potency against respiratory pathogens, including penicillin and quinolone-resistant Streptococcus pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila (6)(7)(8)(9). Nemonoxacin has also been shown to be potent against genital pathogens such as Neisseria gonorrhoeae (9). We compared the in vitro activity of nemonoxacin to that of levofloxacin, azithromycin, and doxycycline against 10 isolates each of C. trachomatis and C. pneumoniae.…”

“…Nemonoxacin has demonstrated potent antibacterial activities against a broad spectrum of Gram-positive cocci and Gram-negative bacilli (6)(7)(8)(9)(10). It has potency against respiratory pathogens, including penicillin and quinolone-resistant Streptococcus pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila (6)(7)(8)(9).…”